Boehringer Ingelheim Recognized as 'Top Employer' by Science Magazine For 13th Consecutive Year

Boehringer Ingelheim named to Science magazine’s “top employers” list in the pharmaceutical and biotechnology industry for the 13th consecutive year.
Author:
Publish date:
Social count:
25

Boehringer Ingelheim today announced it has been named to Science magazine’s annual list of “top employers” within the pharmaceutical and biotechnology industry for the 13th consecutive year. Boehringer Ingelheim was one of only 20 companies recognized. Companies are evaluated based on their industry leadership and corporate direction, academic and intellectual challenges, and work culture and environment.

“We are thrilled once again to be acknowledged by Science magazine, its readers and our colleagues in the pharmaceutical and biotechnology industry,” said Paige Mahaney, PhD, Discovery Research Site Head, US, and Global Head of Biotherapeutics Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc. “Boehringer Ingelheim makes every effort to nurture a passion for discovery and provide our scientists with the diverse, collaborative and open environment needed to do their best work.”

Over the next five years, Boehringer Ingelheim is planning to invest approximately €11 billion in international research and development. Today, the company has more than 100 R&D pipeline projects and boasts more than 70 key innovative partnerships while employing approximately 8,000 people in their four R&D centers of excellence. Overall, the company has invested 24 percent of its 2016 net sales back into R&D for new medicines. Initiatives at Boehringer Ingelheim to foster innovation include Research Beyond Borders, a program that allows our scientists to explore emerging science in and outside of our core therapeutic areas and BI Office Hours, our pioneering mentoring program for early stage biotech companies to engage with our cross functional experts.

“As a privately held company, we have the freedom to take a long-term approach to R&D and our partnerships and our people help to make this innovation happen,” said Mahaney. “We are committed to creating a supportive environment to help our scientists develop medicines that address healthcare’s greatest unmet needs.”

Science magazine, the academic journal of the American Association for the Advancement of Science (AAAS), is one of the world’s top scientific publications. The annual Science top employer survey was based on 6,950 respondents from North America, Europe, and Asia/Pacific Rim, 94 percent of which work in the biotechnology, biopharmaceutical, and pharmaceutical company industries. Survey results were analyzed by an independent consulting group using a mathematical process to determine the driving characteristics of a top employer and to assign a unique score to rate each company’s employer reputation.

Boehringer Ingelheim was also recently recognized to the 2017 Working Mother 100 Best Companies List for the sixth consecutive yea. For the complete results of the Science top employer survey, including individual company rankings, please visit www.sciencecareers.org/TopEmployers2017.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation.

Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit our website to learn more about how we make more health for more people through our Corporate Social Responsibility initiatives.

In 2016, Boehringer Ingelheim achieved net sales of about $17.6 billion (15.9 billion euros). R&D expenditure corresponds to 19.6 percent of its net sales.

For more information please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.